Barclays Maintains Overweight on Sotera Health, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 84.5%

Neg 0% Neu 0% Pos 84.5%

Barclays analyst Luke Sergott maintains Sotera Health (NASDAQ:SHC) with a Overweight and raises the price target from $19 to $22.